MKMaria A. Kurnikova

Maria A. Kurnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria A. Kurnikova has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematological malignancies in constitutional mismatch repair deficiency syndrome

    by Yu. A. Tikhonova, V. V. Klyukhin, D. A. Evstratov, M. A. Klimentova, L. A. Yasko, N. V. Myakova, M. A. Kurnikova, Ю. А. Тихонова, В. В. Клюхин, Д. А. Евстратов, et al.

    Introduction . Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare childhood cancer predisposition syndrome. Aim : to present a unique clinical case of a patient with relapsed T-lymphoblastic lymphoma who was diagnosed with a rare hereditary cancer predisposition syndrome (constitutional mismatch repair deficiency syndrome). Main findings. The cause of CMMRD is considered to be the presence of biallelic germline homo- or compound-heterozygous variants in one of the four MMR genes ( MLH1, MSH2, MSH6 or PMS2 ); inactivation of these genes leads to an increased mutational burden and, consequently, to malignant transformation of cells. Loss of MMR system function underlies the development of a broad spectrum of malignancies in children and adolescents, with the first neoplasm often presenting as a hematological malignancy. The long-term prognosis for patients with CMMRD remains extremely poor due to the high risk of developing metachronous malignancies of other localizations, which necessitates systematic surveillance of this patient group.

  • Open Access

    Features of diagnosis and management of patients with autoimmune lymphoproliferative syndrome caused by somatic defects of the FAS gene

    by Oksana A. Shvets, A. M. Kieva, A. A. Semchenkova, Z. A. Nesterenko, N. Yu. Kan, A. A. Moiseeva, D. V. Bogdanova, E. A. Deordieva, V. I. Burlakov, Zh. A. Kuzminova, et al.

    Introduction. Autoimmune lymphoproliferative syndrome (ALPS) is an inborn error of immunity with impaired FAS-mediated apoptosis. The disease responds well to therapy with the mTORC1-inhibitor sirolimus (SRL). The diagnosis of ALPS is based on the European Society for Immunodeficiencies (ESID) diagnostic criteria, which include the main clinical manifestations in combination mainly with an increased level of double-negative T-lymphocytes (DNT) with the CD3+TCRαβ+CD4–CD8–-phenotype. Most cases of ALPS are caused by germinal mutations in the FAS gene, however, somatic changes in this gene (ALPS-sFAS) can be detected in 15–20% of patients. Aim: to analyze the diagnostic features and clinical presentation before and during SRL treatment in patients with ALPS-sFAS. Materials and methods. In our cohort of patients (n = 6), we analyzed main clinical data (clinical presentation, laboratory and instrumental data), the stages of genetic search and response to SRL therapy. We observed an early onset of the disease (median of 1.7 years), with delayed clinical (median of 3.7 years) and genetic (median of 6.2 years) diagnosis. Results. At the initial examination, only 67% of the patients met the ESID criteria. In 50% of cases with DNT levels 9.9%, somatic mutations in the FAS gene were detected in whole blood DNA, in other cases, we analyzed DNA from sorted DNT cells. All of our patients had previously undescribed somatic mutations in the FAS gene. Our experience of SRL treatment in patients with ALPS-sFAS has been more than 10 years. We observed a good clinical response, as well as continued remission of the disease at a reduced dose of SRL (1.5 mg/m2). In 67% of cases, various adverse events were observed when the SRL dose was 1.5 mg/m2. Conclusion. The obtained results demonstrate the complexity of diagnosis and the need for concern regarding ALPS-cFAS, taking into account the effectiveness of pathogenetic therapy, as well as the importance of a personalized approach in molecular genetic verification of the diagnosis.

  • Open Access

    Tumor predisposition syndromes in patients with SHH group medulloblastoma

    by Marina M. Koldasheva, L. I. Papusha, E. A. Salnikova, A. E. Druy, M. A. Kurnikova, G. A. Novichkova, N. S. Grachev, L. A. Yasko

    Introduction. Medulloblastomas (MB) of the SHH group account for 25–30% of all MBs and are associated with aberrant activation of the intracellular SHH signaling pathway. The incidence of tumor predisposition syndromes (TPS) in patients with MB of the SHH group is about 20%, and this is the highest rate among the other molecular genetic subgroups of MB. In addition, there is significant molecular genetic heterogeneity within the same group, which in turn contributes to variations in survival rates and prognosis. Objective – to analyze the clinical, molecular, and genetic characteristics of TPS in patients with SHH group MB. Materials and methods. This retrospective study included a cohort of 40 patients aged 0 to 18 years with SHH group MB who underwent molecular genetic diagnostic testing between 2018 and 2024 at the D. Rogachev National Medical Research Center. The MB group was determined using NanoString technology. To identify germline mutations, DNA isolated from peripheral blood was examined using the following methods: next-generation sequencing, whole genome sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification. The amplification of the MYC and NMYC genes was detected using fluorescence in situ hybridization. This study did not require approval from the local Ethics Committee, as the analyzed data did not contain any personalized information. Consent was obtained for the peripheral blood testing for TPS and for the publication of the data. Statistical processing and analysis of the data obtained were carried out using the R package version 4.4.2. Overall survival was estimated using the Kaplan–Meier method, and the cumulative incidence of secondary tumors was estimated using the competing risk method. To calculate the overall survival, we used the time from the date of diagnosis to death, and for the cumulative incidence of secondary tumors, we used the time from the date of diagnosis to the development of a secondary tumor, while death was considered a competing event. Results. Fifteen out of 40 patients were diagnosed with TPS. Gorlin syndrome was diagnosed in 7 people, Li–Fraumeni syndrome in 4 patients, there was one case each of Lynch syndrome and neurofibromatosis type 1, and a mutation in the ELP1 gene. One child had a combination of two syndromes (Gorlin and Lynch). The incidence of TPS in the analyzed cohort of 40 people was 37.5%. Thirteen people are alive, 2 patients died. The overall 4-year survival rate was 93% (the 95% confidence interval 82–100). A secondary tumor developed in 4 patients. The 4-year cumulative incidence of secondary tumors was 31% (the 95% confidence interval 6.4–61.0). All patients who developed a secondary tumor had received radiation therapy. Conclusion. When detecting MB of the SHH, it is important to conduct molecular genetic testing for TPS, given their high frequency among patients with MB of this molecular subgroup. The data obtained will help optimize therapy (avoid radiation therapy for young children with confirmed Gorlin syndrome), as well as predict the course of the disease. In addition, genetic testing is necessary for follow-up of such patients and for counseling their parents regarding the familial forms of the described syndromes.

  • Thrombocytopenia of newborns: an observational study

    by E. V. Suntsova, E. V. Deripapa, E. V. Raykina, A. A. Mukhina, Yu. A. Rodina, D. D. Baydildina, L. A. Khachatryan, U. N. Petrova, K. S. Antonova, Z. A. Аbashidze, et al.

    Thrombocytopenia is a common abnormality in neonates. The etiology of neonatal thrombocytopenia ranges from common acquired causes such as immune-mediated thrombocytopenia and sepsis to rare congenital syndromes. There may be objective difficulties in identifying the causes of thrombocytopenia in newborns in the clinical practice. All hematological and nonhematological features of a newborn and his family members must be taken into account for an accurate diagnosis. In our study, we analysed a cohort of 52 children with thrombocytopenia developed in the neonatal period and retrospectively assessed the range of their possible clinical diagnoses. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology of Ministry of Healthcare of the Russian Federation. Perinatal infections and sepsis are often associated with thrombocytopenia. Immune thrombocytopenias are still “diagnoses of exclusion”. In 18 (34.6%) cases, molecular genetic testing confirmed rare congenital syndromes associated with thrombocytopenia. Despite various etiology, donor platelet transfusion with or without intravenous immunoglobulin remains the main treatment method of neonatal thrombocytopenia.

  • Open Access

    Secondary Fisher–Evans syndrome in a child with activated PI(3)kd syndrome and lymphoma

    by Zh. A. Kuzminova, V. V. Fominykh, N. N. Kotskaya, K. V. Mitrakov, A. A. Moiseeva, O. A. Shvets, A. M. Livshits, M. A. Kurnikova

    Evans syndrome, a combination of autoimmune hemolytic anemia and immune thrombocytopenia, is a rare disease in children. In childhood, it may turn out to be one of the first manifestations of a primary immunodeficiency or an immune dysregulation syndrome. Here we present a clinical case of a patient who was initially diagnosed with Evans syndrome and did not respond well to therapy. Based on the results of genetic testing, the child was then diagnosed with primary immunodeficiency, namely, activated PI(3)kd syndrome. During follow-up, the patient developed lymphoma and had to undergo radical treatment (allogeneic hematopoietic stem cell transplantation). The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.


  • Open Access

    A familial case of DICER1 syndrome in a patient with pleuropulmonary blastoma

    by M. V. Teleshova, L. A. Yasko, E. V. Maslenkova, N. N. Merkulov, D. M. Konovalov, M. A. Kurnikova, I. V. Doronina, T. V. Shamanskaya, D. Yu. Kachanov

    Pleuropulmonary blastoma (PPB) is a very rare tumor of childhood that arises from the mesenchyme of the lung and is associated with mutations in the DICER1 gene. The present article describes a familial case of DICER1 syndrome in a patient aged 3 years and 11 months who underwent investigations and treatment for type II/III PPB of the lower lobe of the left lung at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications. The diagnosis was made based on the results of the pathology investigation of the tissue obtained by open biopsy. Furthermore, the diagnosis was confirmed by the review of histological specimens in the International PPB Registry (Minneapolis, USA). According to the data from the chest CT with intravenous contrast enhancement, the tumor was described as a mass consisting of cystic cavities of various calibers accumulating a contrast agent along the periphery, and a solid component. Specific combination treatment was based on the recommendations of the International PPB Registry and included chemotherapy according to the IVADo/IVA regimen and surgical treatment as a local control. Currently, specific treatment has been completed, the patient is alive with no signs of the disease, the follow-up period was 20 months. As regards the patient's family history, he has a sibling (older brother) who was diagnosed with a cystic nephroma at the age of 1 year and 4 months. Molecular genetic testing of the tumor tissues obtained from the patient (PPB) and his sibling (cystic nephroma) revealed pathogenic somatic variants in the DICER1 gene. Along with the somatic genetic variants, another pathogenic variant was found in both children, the germline status of which was confirmed. The germline variant in the DICER1 gene was inherited from the mother. Thus, the investigations confirmed a familial case of DICER1 syndrome. The case described in this article indicates that families in which DICER1 syndrome was found require special management aimed at early detection of tumors and non-tumor conditions associated with this syndrome in the carriers of pathogenic alleles.

  • PRIMARY HYPERPARATHYROIDISM CAUSED BY THE PARATHYROID ADENOMA ECTOPIC IN THE THYMUS: A CLINICAL CASE

    by N.G. Uskova, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, N.V. Babaskina, E.Yu. Il’ina, D.S. Abramov, M.A. Kurnikova, D.G. Akhaladze, N.S. Grachev

    Primary hyperparathyroidism (or PHPT) is a rare pediatric disease occurring in 1 case per 200 to 300 thousand children. The most common cause of PHPT in the adult population is a solitary parathyroid (PT) adenoma with up to 16% of PT adenomas having an ectopic location. There are no epidemiological data on pancreatic adenomas in pediatric population including atypically located ones, and clinical data are extremely scarce. This article describes a clinical observation of an adolescent patient with PHPT whose disease has been manifested with increased fragility and deformation of the bones of the skeleton. Only one year after the onset of primary symptoms a complex set of diagnostic measures was initiated, as a result of which a diagnosis was established: PHPT against the background of adenoma of the pancreas, ectopic in the left lobe of the thymus. The surgical treatment was carried out in the amount of thoracoscopic hemithymectomy which led to the relief of hyperparathyroidism. Despite the surgical intervention the systemic osteoporosis and persistent pathological changes in the bone skeleton that have been formed by the time of diagnosis require long-term observation and treatment of the patient by a pediatric endocrinologist, pediatric orthopedist and rehabilitologist. Thus, based on the presented clinical observation, the conclusion is as follows: in order to minimize the risk of disability in children and adolescents with PHPT it is extremely important to establish the correct diagnosis as early as possible coupled with the timely etiotropic and pathogenetic treatment.

  • Open Access

    Germinal and somatic genetic variants of NF1 in neuroblastoma: own experience and literature review

    by N. A. Andreeva, T. V. Shamanskaya, D. Yu. Kachanov, L. A. Yasko, M. A. Kurnikova, R. Kh. Abasov, A. E. Druy

    Introduction. Neuroblastoma (NB) is the most common embryonic extracranial malignant neoplasm in children. The contribution of the NF1 gene to the development of NB is discussed in the literature, but there is no evidence of the pathogenetic role of NF1 gene aberrations in NB. According to various literature sources, the occurrence of pathogenic variants in the NF1 gene in the general cohort of patients with NB does not exceed 1–6 %.Materials and methods. The molecular genetic examination by next generation sequencing (NGS) was performed in 77 patients with NB during the period from April 2019 to July 2021 in the Laboratory of Molecular Oncology Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology. The staging of patients was carried out within the framework of the international staging system, stratification into risk groups and therapy according to the protocol of the German Group for the study of NB GPOH NB-2004. International criteria of the response assessment system for patients with NB were used to assess the response to treatment. Calculations of event-free and overall survival by the Kaplan–Mayer method for the follow-up period up to 12.01.2022 were performed.Results and discussion. The cohort of patients included in the study was represented by patients with an initially unfavorable prognosis. Patients were divided into 3 groups: without pathogenic variants in genes belonging to the RAS-RAF-MEK pathway and TP53 – “RAS-/ TP53-” (n = 43), with clinically significant variants in the NF1 gene – “NF1+” (n = 12), clinically significant variants in the genes of RAS-RAF-MEK and TP53 pathway – “RAS+/TP53+” except NF1 (n = 22). The median age for the entire group of patients at the time of diagnosis was 41 months (0.1–173 months). Boys prevailed over girls with a ratio of 1.5:1. Patients with stage 4 of the disease according to the INSS classification prevailed – 81.8 % (63/77), high-risk groups according to the NB-2004 protocol – 77.9 % (60/77).In our study 13 clinically significant variants in NF1 were identified in 12 patients (15.6 %), of which 4 were germinal, 9 were somatic. The frequency of detection of pathogenic aberrations in the NF1 gene was much higher than the literature data, which can be associated with a selective cohort of studied patients with an unfavorable prognosis and patients with suspected hereditary genetic syndrome. The presentation of adverse events was observed in 83.3 % of patients, more often against the background of specific therapy (in 60 % of cases), which may be due to the rapid acquisition of NB chemoresistance, among other things. When comparing the three groups, it was shown that the frequency of objective responses to induction therapy was statistically significantly lower in the group of patients “NF1+”, when compared with other groups (p = 0.015; p = 0.024), which may also indicate the chemoresistance of NF1-aberrated NB. When analyzing survival there was no statistical difference between the compared groups.Conclusions. The data obtained by us do not allow us to consider the presence of genetic variants in NF1 separately as a prognostic factor, however, it can be assumed that a group of patients with an unfavorable prognosis may be enriched with cases with mutations in the NF1 gene. Refractory course of the disease/development of adverse events in the presence of genetic variants of NF1, causing the activation of the RASRAF- MEK signaling pathway, leads to the induction of tumor chemoresistance. The presence of clinical significance of aberrations in the NF1 gene does not lead to a statistically significant difference in prognosis when compared with patients with aberrations in other components of the RAS-RAF-MEK pathway, however, longer catamnestic follow-up of patients is necessary.Currently, there are no effective drugs for the treatment of NF1-associated NB in clinical practice that requires further study of the mechanisms of chemoresistance development in such patients. Understanding the molecular and genetic features of the course of NF1-associated NB can become the basis for the development of personalized therapy in the future.

  • Open Access

    SMARCA4-associated malignant rhabdoid tumors: case report and literature review

    by N. A. Andreeva, E. I. Lyudovskikh, D. M. Konovalov, M. V. Teleshova, A. M. Mitrofanova, M. A. Kurnikova, L. A. Yasko, A. E. Druy, M. Yu. Goroshkova, T. V. Shamanskaya, et al.

    Malignant rhabdoid tumor (MRT) is a rare malignant neoplasm of childhood, characterized by an aggressive course and an extremely unfavorable prognosis. The frequency of MRT outside the central nervous system (extracranial MRT) is 0.02–0.03 per 100,000 children. In most cases, MRT is based on an inactivating mutations of the tumor suppressor gene SMARCB1, which leads to the absence of expression of the SMARCB1 ((INI1/hSNF5/BAF47) protein in tumor cells. Aberrations of the SMARCA4 gene, which is an extremely rare molecular event, have been described among the MRTs expressing SMARCB1 (INI1). Few case reports have been described in the international literature.This article contains a description of a clinical case of a patient diagnosed with soft tissue MRT with SMARCA4 gene alteration. The distinctive features of the presented case are the congenital nature of the tumor, atypical localization, and extremely aggressive clinical course of the disease. On the example of the described clinical case, diagnostics of SMARCA4-associated MRT are presented, as well as the place of molecular methods in diagnosis verification. In addition, it is highlighted that the detection of somatic changes in the SMARCB1 and SMARCA4 genes requires additional investigation of their germinal status to exclude or confirm the rhabdoid tumor predisposition syndrome.


  • De novo TP53 germline activating mutations in two patients with the phenotype mimicking Diamond–Blackfan anemia

    by Daria Fedorova, Galina Ovsyannikova, Maria Kurnikova, Anna Pavlova, Tatiana Konyukhova, Alexey Pshonkin, Nataliya Smetanina

    Diamond–Blackfan anemia (DBA) is an inherited bone marrow failure syndrome, associated with mutations in ribosomal protein (RP) genes. Growing data on mutations in non‐RP genes in patients with DBA‐like phenotype became available over recent years. We describe two patients with the phenotype of DBA (onset of macrocytic anemia within the first year of life, paucity of erythroid precursors in bone marrow) and germline de novo variants in the TP53 gene. Both patients became transfusion independent, probably due to L‐leucine therapy. The possible role of TP53 variants should be considered in patients with DBA‐like phenotype and no mutations in RP genes.